医学
类风湿性关节炎
叙述性评论
背景(考古学)
重症监护医学
贾纳斯激酶
人口
甲氨蝶呤
大流行
梅德林
2019年冠状病毒病(COVID-19)
内科学
疾病
古生物学
环境卫生
细胞因子
传染病(医学专业)
生物
政治学
法学
作者
Carlo Garaffoni,Antonella Adinolfi,Alessandra Bortoluzzi,Georgios Filippou,Alessandro Giollo,Garifallia Sakellariou,Silvia Sirotti,Nicola Ughi,Carlo Alberto Scirè,Ettore Silvagni
出处
期刊:Clinical and Experimental Rheumatology
日期:2022-05-16
被引量:9
标识
DOI:10.55563/clinexprheumatol/1sjgyr
摘要
New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last year. Specifically, updated guidelines on pharmacological and non-pharmacological management of RA have emphasised the necessity of global patient's care, and have shifted the role of some older drugs, such as glucocorticoids and methotrexate. In addition, the long-term safety of Janus kinase inhibitors was investigated and reinforced. With respect to the coronavirus-19 pandemic, reassuring data on the efficacy and safety of vaccinations in the RA population were acquired, as well as on the potential role of telemedicine in RA management. Machine learning prediction models and biomarkers development have emerged as promising innovations in the area of precision/personalised medicine, appearing to encourage future expansion.In this narrative review, the authors aim to give their specific point of view on the most relevant and potentially impacting novelties published during 2021 and early 2022 in the context of RA management.
科研通智能强力驱动
Strongly Powered by AbleSci AI